We found that inhibition of tumor growth mediated by the infusion of CD3+ T cells was significantly enhanced by rhIL-33 administration, which synergized with 5-FU treatment, resulting in strong tumor regression (Figure 8B-C), prolonged survival (Figure 8D), and increased expression of the apoptotic marker cleaved-caspase 3 (Figure S7A). The gene discussed is CASP3; the disease is neoplasm.